|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Geographic Variation in the Use of Doublet Therapy for Metastatic Prostate Cancer |
| Samuel Washington III, MD, MAS
|
| Samuel Washington joins Alicia Morgans in a conversation on a population-based analysis evaluating geographic variations in the utilization of doublet therapy for metastatic prostate cancer patients. This project aimed to understand the real-world utilization of these combination strategies, as well as its geographic variation focusing on how who you are and where you get your care, impacts the type of care that you're going to get. |
|
|
|
|
|
|
|
|
|
|
|
| First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer
|
| Evan Yu, MD
|
| Evan Yu discusses the changing landscape of metastatic hormone-sensitive prostate cancer treatment with Alicia Morgans. Dr. Yu provides an overview of the many important questions and concerns clinicians must address in sequencing treatment for mCRPC patients in light of novel hormone therapy agents and the opportunity for triplet therapy.
|
|
|
|
|
|
|
|
|
|
|
|
| Early Triplet Combination Therapy Shows Increased Overall Survival: The ARASENS Trial |
| Tomasz M. Beer, MD, FACP |
| Alicia Morgans is joined by Tomasz Beer for a discussion on the ARASENS trial. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC) and ECOG performance status 0 or 1. The most important finding was androgen deprivation therapy (ADT) plus docetaxel plus darolutamide produced a better overall survival than ADT plus docetaxel and placebo. |
|
|
|
|
|
|
|
|
|
|
|
| mCSPC Couplet vs Triplet Therapy LUGPA 2022 Presentation
|
| Alicia Morgans, MD, MPH
|
| At the 2022 Large Urology Group Practice Association (LUGPA) Annual Meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC).
|
|
|
|
|
|
|
|
|
|
|
|
| State of the Art Lecture: mHSPC - Doublet vs Triplet Combination Therapy
|
| Eleni Efstathiou, MD, Ph.D.
|
| The 37th Annual European Association of Urology Congress was host to a session about the management of metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Eleni Efstathiou was tasked with discussing the current state of doublet versus triplet combination therapy in the management of metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
|
|
|
|
| Chemotherapy and Advanced Androgen Blockage, Alone or Combined, for Metastatic Hormone-Sensitive Prostate Cancer, A Systematic Review and Meta-Analysis - Beyond the Abstract
|
| Giuseppe Fallara, MD
|
| The main question is whether the benefit in terms of OS and PFS seen between triplet therapy vs. docetaxel plus ADT holds true also vs. AAB plus ADT. In other words, is docetaxel needed? To disentangle this question, the authors conducted a systematic review and meta-analysis on chemotherapy and AAB alone or combined for men with mHSPC. To do so, we relied on survival data reconstruction. We were able to digitalize the Kaplan-Meier curves for PFS and OS and to extrapolate quasi-individual survival data, i.e. for each individual the time from randomization to either censoring or event and the event of censoring itself.
|
|
|
|
|
|
|
|
|
|
|
| Overall Safety and Incidences of Adverse Events by Time Interval with Darolutamide Plus Androgen Deprivation Therapy and Docetaxel in the ARASENS Trial
|
| E. David Crawford, MD
|
| David Crawford presented a post hoc analysis of safety and adverse events among men with metastatic hormone-sensitive prostate cancer (mHSPC) treated in the context of the ARASENS trial. ARASENS demonstrated that the triplet combination of darolutamide+androgen-deprivation therapy (ADT)+docetaxel significantly reduced risk of death by 32.5% (hazard ratio [HR] 0.675; 95% confidence interval [CI] 0.568–0.801; P <0.0001) compared to the doublet of ADT+docetaxel.
|
|
|
|
|
|
| Recurrent Prostate Cancer: Treatment Landscape of Hormone-Sensitive Recurring M1 Prostate Cancer
|
| Ursula M. Vogl, MD, MBA
|
| Ursula Vogl discusses the treatment landscape of hormone sensitive recurrent M1 prostate cancer. Dr. Vogl starts her presentation by noting that from a nomenclature standpoint, hormone-sensitive recurring M1 prostate cancer is the same as metachronous metastatic hormone-sensitive prostate cancer, which is typically stratified into low-volume and high-volume disease.
|
|
|
|
|
|
| Treatment Intensification Strategies in mHSPC: Triplets and More
|
| Christopher Sweeney, MBBS
|
| The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on the management of metastatic hormone-sensitive prostate cancer (mHSPC) and a presentation by Dr. Christopher Sweeney discussing treatment intensification strategies in mHSPC, specifically triplet therapies. Dr. Sweeney started by highlighting that there are several life-prolonging treatment options for men with mHSPC.
|
|
|
|
|
|
 |
